597 related articles for article (PubMed ID: 36183125)
1. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
Alu A; Lei H; Han X; Wei Y; Wei X
J Hematol Oncol; 2022 Oct; 15(1):138. PubMed ID: 36183125
[TBL] [Abstract][Full Text] [Related]
2. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
Shirley M
Target Oncol; 2022 Jan; 17(1):69-84. PubMed ID: 34905129
[TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
4. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
5. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
6. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
7. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
8. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
Dostálová H; Kryštof V
Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
[TBL] [Abstract][Full Text] [Related]
9. Bruton's Tyrosine Kinase Inhibitors: Recent Updates.
Fares A; Carracedo Uribe C; Martinez D; Rehman T; Silva Rondon C; Sandoval-Sus J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396884
[TBL] [Abstract][Full Text] [Related]
10. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Wu J; Zhang M; Liu D
J Hematol Oncol; 2016 Mar; 9():21. PubMed ID: 26957112
[TBL] [Abstract][Full Text] [Related]
11. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
12. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
13. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
15. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
[TBL] [Abstract][Full Text] [Related]
16. Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
Lin DY; Andreotti AH
PLoS One; 2023; 18(8):e0290872. PubMed ID: 37651403
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Davids MS; Brown JR
Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
[TBL] [Abstract][Full Text] [Related]
18. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.
Wen T; Wang J; Shi Y; Qian H; Liu P
Leukemia; 2021 Feb; 35(2):312-332. PubMed ID: 33122850
[TBL] [Abstract][Full Text] [Related]
20. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Muñoz J; Wang Y; Jain P; Wang M
Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
